### PATENT COOPERATION TREATY

	From the INTERNATIONAL BUREAU		
PCT	To:		
NOTIFICATION OF ELECTION	Assistant Commissioner for Patents		
(DCT D.U. C1 2)	United States Patent and Trademark		
(PCT Rule 61.2)	Office Box PCT		
	Washington, D.C.20231		
Data of modification and	ETATS-UNIS D'AMERIQUE		
Date of mailing (day-month-year) 03 October 2000 (03.10.00)	in its capacity as elected Office		
International application No.	Applicant's or agent's file reference		
PCT/GB00/00281	PCB/D088334PWO		
International filing date (day month year)	Priority date (day month/year)		
01 February 2000 (01.02.00)	05 February 1999 (05.02.99)		
Applicant			
POMFRETT, Christopher, John, Douglas et al			
The designated Office is hereby notified of its election made	de:		
X in the demand filed with the International Preliminar	y Examining Authority on:		
01 September	r 2000 (01.09.00)		
in a notice effecting later election filed with the Inter	national Bureau on:		
<del></del>			
2. The election X was			
was not			
4.10	day and a D to 22 and a sixth of a to a local		
made before the expiration of 19 months from the priority Rule 32.2(b).	date or, where Rule 32 applies, within the time limit under		
-	Autrorized officer		
The International Bureau of WIPO 34, chemin des Colombettes	S. Mafla		
1211 Geneva 20, Switzerland			
Facrimile No.: (41-22) 740-14, 39	Telest rane (soci (41-22) gardalaa		

#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau



## 

## (43) International Publication Date 10 August 2000 (10.08.2000)

#### PC7

English

# (10) International Publication Number WO 00/45832 A3

- (51) International Patent Classification<sup>7</sup>: A61K 38/08, A61P 23/00
- (21) International Application Number: PCT/GB00/00281
- (22) International Filing Date: 1 February 2000 (01.02.2000)
- (25) Filing Language:
- (26) Publication Language: English
- (30) Priority Data:

9902469.7	5 February 1999 (05.02.1999)	GB
60/120,326	17 February 1999 (17.02.1999)	US
60/155,661	24 September 1999 (24.09.1999)	US

- (71) Applicant (for all designated States except US): THE VICTORIA UNIVERSITY OF MANCHESTER [GB/GB]; Oxford Road, Manchester M13 9PL (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): POMFRETT, Christopher, John, Douglas [GB/GB]; 17 Manifold Close, Elworth, Sandbach, Cheshire CW11 1XP (GB). ALKIRE, Michael [US/US]; 2959 Java Road, Costa Mesa, CA 92626 (US). HAIER, Richard [US/US]; 10 Harvey Court, Irvine, CA 92612 (US). FALLON, Jim [US/US]; 5 Dickens Court, Irvine, CA 92612 (US).

- (74) Agent: BANFORD, Paul, Clifford; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- (88) Date of publication of the international search report: 30 November 2000

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

/45832 A

(54) Title: REGULATION OF ANAESTHESIA

(57) Abstract: The present invention concerns uses of compounds which modulate Delta-Sleep Inducing Peptide active for regulating anaesthesia and methods of evaluating the anaesthetic needs of a subject comprising assaying a sample taken from the subject for the presence of Delta-Sleep Inducing Peptide.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
ВВ	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## **PCT**

#### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report						
PCB/D088334PW0	ACTION (Form PC1/ISA/2	(20) as well as, where applicable, item 5 below.						
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)						
PCT/GB 00/00281	01/02/2000	05/02/1999						
Applicant	Applicant							
THE VICTORIA UNIVERSITY O	F MANCHESTER et al							
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Autl ansmitted to the International Bureau.	hority and is transmitted to the applicant						
	-							
This International Search Report consists    X	of a total of sheets.  a copy of each prior art document cited in this	report						
it is also accompanied by	a copy of each phor art document cited in this	тероп.						
Basis of the report								
	international search was carried out on the bar less otherwise indicated under this item.	sis of the international application in the						
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of t	he international application furnished to this						
		nternational application, the international search						
was carried out on the basis of the contained in the internation	e sequence listing : onal application in written form.							
filed together with the inte	ernational application in computer readable form	m.						
T furnished subsequently to	this Authority in written form.							
T furnished subsequently to	this Authority in computer readble form.							
the statement that the sub- international application a	osequently furnished written sequence listing d is filed has been furnished.	loes not go beyond the disclosure in the						
the statement that the info furnished	ormation recorded in computer readable form i	s identical to the written sequence listing has been						
2. X Certain claims were fou	nd unsearchable (See Box I).							
3. Unity of invention is lac	king (see Box II).							
4. With regard to the <b>title</b> ,								
The text is approved as su	ibmitted by the applicant.							
	shed by this Authority to read as follows:							
5 1450								
5. With regard to the <b>abstract</b> ,	shmitted by the applicant							
	shed, according to Rule 38.2(b), by this Authori e date of mailing of this international search rep							
6. The figure of the <b>drawings</b> to be pub								
as suggested by the appl	icant.	None of the figures.						
because the applicant fair	led to suggest a figure.	<del></del>						
because this figure better	characterizes the invention.							
Î .								

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-4, 8-9

Present claims 1-4 and 8-9 relate to a compound defined by reference to a desirable characteristic or property, namely the fact that it modulates (claims 1, 9), promotes/mimics (claims 2, 4) or inhibits (claim 8) Delta-Sleep inducing peptide activity.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the uses and methods claimed when the compound is Delta-Sleep inducing peptide self, including its phosphorylated and cyclic derivatives (see page 4 of the description) as well as Melatonin, Dalargin and Neokyotorphin (see page 8 of the description).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

A. CI.ASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/08 A61P23/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{C07K} \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, EPO-Internal, STRAND, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 SUDAKOV K V: "ANTISTRESS EFFECTS OF DELTA-SLEEP INDUCING PEPTIDE" Database accession no. PREV199294101504 XP002146452 abstract & FIZIOLOGICHESKII ZHURNAL SSSR IMENI I M SECHENOVA, vol. 77, no. 3, 1991, pages 1-13, ISSN: 0015-329X	4-7

Y Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents :  "A" document defining the general state of the art which is not considered to be of particular relevance.	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
<ul> <li>"E" earlier document but published on or after the international filling date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filling date but later than the priority date claimed</li> </ul>	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
4 September 2000	18/09/2000
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fernandez y Branas,F

1



nternational Application No PCT/GB 00/00281

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199840 Derwent Publications Ltd., London, GB; Class B04, AN 1998-465470 XP002146453	1-3,8,9
	& RU 2 104 717 C (NOVOK DOCTORS TRAINING INST), 20 February 1998 (1998-02-20) abstract	
X	EP 0 513 702 A (BIELLA GABRIELE ;FRASCHINI FRANCO (IT); STANVOK BOJIDAR (IT); FERI) 19 November 1992 (1992-11-19) the whole document	1-3,8,9
A	US 4 444 758 A (SCHERSCHLICHT RICHARD R ET AL) 24 April 1984 (1984-04-24) the whole document	1-13
А	US 4 165 312 A (SCHOENENBERGER GUIDO A) 21 August 1979 (1979-08-21) the whole document	1-13


### IN RNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/00281

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
RU 2104717 C	20-02-1998	NONE	
EP 0513702 A	19-11-1992	IT 1251544 B AT 142877 T AT 184792 T DE 69213814 D DE 69230046 D DE 69230046 T DK 513702 T EP 0713701 A ES 2093735 T ES 2139132 T GR 3022060 T JP 5155769 A US 5430029 A	17-05-1995 15-10-1996 15-10-1999 24-10-1996 03-04-1997 28-10-1999 31-05-2000 30-12-1996 29-05-1996 01-01-1997 01-02-2000 31-03-1997 22-06-1993 04-07-1995
US 4444758 A	24-04-1984	AU 552547 B AU 8375682 A CA 1188989 A DE 3218761 A EP 0065747 A IE 53395 B IL 65782 A IT 1152116 B JP 1688906 C JP 3054089 B JP 58023630 A PH 17981 A US 4496545 A ZA 8203369 A	05-06-1986 25-11-1982 18-06-1985 16-12-1982 01-12-1982 09-11-1988 30-08-1985 31-12-1986 11-08-1992 19-08-1991 12-02-1983 26-02-1985 29-01-1985 30-03-1983
US 4165312 A	21-08-1979	CH 634331 A DE 2828433 A FR 2396016 A GB 2000511 A,B JP 1468817 C JP 54039050 A JP 63017840 B	31-01-1983 11-01-1979 26-01-1979 10-01-1979 30-11-1988 24-03-1979 15-04-1988



#### **CLAIMS**

- 1. The use of a compound which modulates Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for regulating anaesthesia.
- 2. The use according to claim 1, wherein the compound promotes or mimics Delta-Sleep Inducing Peptide activity and the medicament promotes or induces anaesthesia.
- 3. The use according to claim 2 wherein the compound is for use in conjunction with another anaesthetic agent.
- 4. The use of a compound which promotes Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for promoting or inducing sedation.
- 5. The use according to any one of claims 2 4, wherein the compound is Delta-Sleep Inducing Peptide or biologically active fragments and derivatives thereof.
- 6. The use according to claim 5 wherein the compound is a nonapeptide with the amino acid sequence:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

- or biologically active fragments and derivatives thereof.
- 7. The use according to claim 6 wherein at least one amino acid or derivative thereof is phosphorylated.
- 8. The use according to claim 1, wherein the compound inhibits Delta-Sleep Inducing Peptide activity and the medicament promotes or induces recovery from anaesthesia.

WO 00/45832 PCT/GB00/00281

17

- 9. A method of regulating anaesthesia comprising administering to a subject in need of treatment a compound which modulates Delta-Sleep Inducing Peptide activity.
- 10. A method of evaluating the anaesthetic needs of a subject to be anaesthetised comprising assaying a sample taken from the subject for the presence of Delta-Sleep Inducing Peptide.
- 11. The method according to claim 10, wherein the sample is a blood or urine sample.
- 12. The method according to claim 10 or 11, wherein higher than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have lower than average anaesthetic requirements.
- 13. The method according to claim 10 or 11, wherein lower than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have higher than average anaesthetic requirements.

## PATENT COOPERATION TREATY

# PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or a	gent's file reference		<del> </del>		
PCB/D0883	34PWO	FOR FURTHER	ACTION	See Notific Preliminan	ation of Transmittal of International / Examination Report (Form PCT/IPEA/416)
PCT/GB(10/C	International application No.         Internation           PCT/GB(0/00281         01/02/20		nal filing date (day/month/year) 200		Priority date (day/month/year) 05/02/1999
International Pa A61K38/08	lent Classification (IPC) or r	national classification and	IPC		0.02/1333
Applicant					
THE VICTOR	IA UNIVERSITY OF M	MANCHESTER et al			
<ol> <li>This intern and is tran</li> </ol>	ational preliminary exam smitted to the applicant	nination report has bee according to Article 36	en prepared b	y this Inter	national Preliminary Examining Authority
2. This REPO	RT consists of a total of	6 sheets, including ti	nis cover she	et.	
⊠ This re been a	port is also accompanie	d by ANNEXES, i.e. s	heets of the c	description,	claims and/or drawings which have ifications made before this Authority
	xes consist of a total of		o mon denome	onder the	PG1).
3. This report o	ontains indications relat	ing to the following ite	ms:		
1 🖾	Basis of the report				
, II 🗆 I	Priority				
III 🖾 1	Ion-establishment of op	inion with regard to no	oveltv inventi	ve stan an	diadours of the
	ack or army or myennon	1			
			egard to nove	elty, inventi	ve step or industrial applicability;
νι <u> </u>	ertain documents cited				
VII	ertain defects in the inte	ernational application			
VIII 🗆 C	ertain observations on t	he international applic	ation		
te of submission o	of the demand				
/09/2000			Date of compl	etion of this i	eport
			18.01.2001		
ımınary examining	dress of the international gauthority:  n Patent Office		Authorized office	cer	e or is constituted
<u>)</u> )) D-80298 Tel. +49	Munich 89 2399 - 0 Tx: 523656 ep 89 2399 - 4465	mu d	Deck, A		(Line of State of Sta
1 47. +43	00 2000 - 4465		Talasti		( S. )

# PATENT COOPERATION TREATY

From the

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

BANFORD, Paul C.
MARKS & CLERK
Sussex House
83-85 Mosley Street
Manchester M2 3LG
GRANDE BRETAGNE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing (day/month/year)

18.01.2001

Applicant's or agent's file reference PCB/D:088334PWO

International application No.

PCT/GB00/00281

International filing date (day/month/year)

Priority date (day/month/year) 05/02/1999

IMPORTANT NOTIFICATION

01/02/2000

Applicant

THE VICTORIA UNIVERSITY OF MANCHESTER et al

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office D-80298 Munich

Tel +49 89 2399 - 0 Tx: 523656 epmu d

Fax: +49 89 2399 - 4465

Authorized officer

Hundt, D

Tel.+49 89 2399-8042



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00281

	1.	Basis of the report				
	1.	This report has beer response to an invita the report since they Description, pages	n drawn on the basis of (substit ation under Article 14 are referm do not contain amendments (F :	ute sheets whic ed to in this rep Rules 70.16 and	h have been furnis ort as "originally fil ' 70.17).):	shed to the receiving Office in led" and are not annexed to
		1-15	as originally filed			
		Claims, No.:				
		1-12	as received on	14/12/2000	with letter of	14/12/2000
2.			guage, all the elements marked international application was fil available or furnished to this At	, a.ness one	i wise indicated un	der this item.
		the language of a the language of pu	translation furnished for the publication of the international aptranslation furnished for the pur	rposes of the in	ternational search	(under Rule 23.1(b)).
3.	W int	ith regard to any nuc ernational preliminar	leotide and/or amino acid sed y examination was carried out d	quence disclose on the basis of t	ed in the internatio he sequence listin	nal application, the g:
] ] ]		filed together with the furnished subsequent furnished subsequent that the international appropriate together with the functional appropriate together files and the functional appropriate files an	ernational application in written the international application in captly to this Authority in written the subsequently furnished written subsequently furnished written as filed has been furnished in complication as filed has been furnished.	omputer readab form. er readable form tten sequence li shed	n. sting does not go	beyond the disclosure in the written sequence
4. T	he	amendments have r	esulted in the cancellation of:			
	]	the description,	pages:			
		the claims,	Nos.:			
	]	the drawings,	sheets:			
5. 🗆		This report has been considered to go bey	established as if (some of) the ond the disclosure as filed (Rul	amendments h e 70.2(c)):	ad not been made	, since they have been

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00281

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

		report.)				11 to ander herri i and annexed to thi
	6. A	dditional observations	s, if nece	ssary:		
	1. 11	vious), or to be indus	the claim trially ap	ned inven plicable h	rd to novelty, inventive step a on appears to be novel, to invol ve not been examined in respe	
	⊠		··a·appii	oanon.		
	becau	se:				
	Ø	the said internationa does not require an see separate sheet		ition, or thonal preli	e said claims Nos. 9-12 relate to inary examination (specify):	the following subject matter which
		the description, clain that no meaningful o	ns or dra pinion co	wings ( <i>in</i> ould be fo	licate particular elements below med (specify):	) or said claims Nos. are so unclear
	. 🗆	the claims, or said clace could be formed.	aims No:	s. are so	nadequately supported by the d	escription that no meaningful opinion
		no international searc	ch report	has beer	established for the said claims	Nos
2	. A me and/ Instr	eaningful international or amino acid sequen uctions:	l prelimir ce listing	ary exam I to comp	nation report cannot be carried with the standard provided for	out due to the failure of the nucleotide in Annex C of the Administrative
		the written form has n	ot been	furnished	or does not comply with the star	ndard
		the computer readable	e form ha	as not be	n furnished or does not comply	with the standard.
٧.	Reas citati	oned statement und ons and explanation	er Artic is suppo	le 35(2) w orting su	th regard to novelty, inventive	e step or industrial applicability;
1.	State					
	Nove	lty (N)	Yes: No:	Claims Claims	1-12	
	Inven	tive step (IS)	Yes: No:	Claims Claims	1-12	
	Indust	rial applicability (IA)	Yes:	Claims	1-8	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00281

No: Claims

2. Citations and explanations see separate sheet

Form PCT/IPEA/409 (Roype LVIII Shoot of Children

INTERNATIONAL PRELIMINARY

EXAMINATION REPORT - SEPARATE SHEET

International application No. PCT/GB00/00281

## Concerning section III:

Claims 9-12 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

## Concerning section V:

The following documents are referred to in this communication; the numbering will be adhered to in the rest of the procedure:

- D1: DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 SUDAKOV K V: 'ANTISTRESS EFFECTS OF DELTA-SLEEP INDUCING PEPTIDE' Database accession no. PREV199294101504 XP002146452 & FIZIOLOGICHESKII ZHURNAL SSSR IMENI I M SECHENOVA, vol. 77, no. 3, 1991, pages 1-13, ISSN: 0015-329X
- D2: DATABASE WPI Section Ch, Week 199840 Derwent Publications Ltd., London, GB; Class B04, AN 1998-465470 XP002146453 & RU 2 104 717 C (NOVOK DOCTORS TRAINING INST), 20 February 1998 (1998-02-20)
- D3: EP-A-0 513 702 (BIELLA GABRIELE ;FRASCHINI FRANCO (IT); STANVOK BOJIDAR (IT); FERI) 19 November 1992 (1992-11-19)

D1 describes the antistress activity of DSIP.

D2 discloses the use of dalargin, a DSIP antagonist according to the present invention, for protecting patients with Leriche's syndrome during operations.

D3 describes the use of melatonin, another DSIP antagonist according to the present invention, in the therapy of sleep disorders and in the pre-anaesthetic medication.

None of the prior art documents describe the use of DSIP or biologically active fragments and derivatives thereof for the manufacture of a medicament for regulating anaesthesia, not for evaluating the anaesthetic needs of a subject. The subject-matter of claims 1 to 12 is therefore new.

# INTERNATIONAL PRELIMINARY International application No. PCT/GB00/00281 EXAMINATION REPORT - SEPARATE SHEET

The closest prior art is the document D3 which describes the use of a compound which modulates DSIP activity for inducing sedation or in the pre-anaesthetic medication. The problem underlying the invention is to find new compounds useful either for inducing anaesthesia or for promoting recovery from anaesthesia.

The invention solves the problem, the solution being the use of the nonapeptide DSIP itself (or derivatives) for inducing anaesthesia or sedation, and the use of DSIP antagonists to promote recovery from anaesthesia.

The subject-matter of claims 1 to 12 is inventive because

- the anaesthetic activity of DSIP is neither taught nor suggested in the available prior art;
- DSIP antagonists, e.g. melatonin or dalargin, are only described for anaesthetizing patients, not for promoting their recovery from anaesthesia;
- a method of evaluating the anaesthetic needs of a subject by assessing the presence of DSIP in a sample is neither described nor suggested in the prior art.

## Industrial applicability:

For the assessment of the present claims 9-12 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

16

#### **CLAIMS**

- 1. The just of Delta-Sleep Inducing Peptide or biologically active fragments and derivatives thereof for the manufacture of a medicament for regulating anaesthesia.
- 2. The use according to claim 1 for promoting or inducing anaesthesia.
- 3. The use according to claim 1 for promoting or inducing sedation.
- 4. The use according to any preceding claim wherein the compound is for use in conjunction with another anaesthetic agent.
- 5. The use according to any preceding claim wherein the compound is a nonapeptice with the amino acid sequence:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu or biologically active fragments and derivatives thereof.

- 6. The use according to claim 5 wherein at least one amino acid or derivative thereof is phosphorylated.
- 7. The use of a compound that decreases Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for promoting or inducing recovery from anaesthesia.
- 8. The use according to claim 7 wherein the compound is melatonin, dalargin or neokyotorphin..
- 9. A method of evaluating the anaesthetic needs of a subject to be anaesthetised comprising assaying a sample taken from the subject for the presence of Delta-Sleep Inducing Peptide.

- 10. The method according to claim 9, wherein the sample is a blood or urine sample.
- 11. The method according to claim 9 or 10, wherein higher than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have lower than average anaesthetic requirements.
- 12. The method according to claim 9 or 10, wherein lower than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have higher than average anaesthetic requirements.